Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.45 |
| ▸ | NOS1 | P29475 | 7/20 | 0.44 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | NOS3 | P29474 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169147 | 0.90 | NOS1 (0.44) | TACR1NOS1NOS2NOS3 | |
| SCHEMBL22028466 | 0.90 | TACR1 (0.52) | TACR1NOS1NOS2NOS3KCNH2 | |
| SCHEMBL15077165 | 0.83 | KCNH2 (0.51) | TACR1NOS1NOS2NOS3KCNH2 | |
| SCHEMBL445763 | 0.82 | TACR1 (0.44) | TACR1NOS1NOS2NOS3KCNH2 | |
| SCHEMBL21400112 | 0.81 | NOS1 (0.47) | TACR1NOS1NOS2NOS3 | |
| Hydrochloric Acid SCHEMBL787937 | 0.81 | TACR1 (0.43) | TACR1NOS1NOS2NOS3KCNH2 | |
| SCHEMBL10104524 | 0.79 | TACR1 (0.41) | TACR1NOS1NOS2NOS3 | |
| SCHEMBL10104293 | 0.79 | NOS1 (0.44) | TACR1NOS1NOS2NOS3KCNH2 | |
| SCHEMBL17365391 | 0.78 | NOS1 (0.41) | TACR1NOS1NOS2NOS3CCR2 | |
| SCHEMBL14492896 | 0.78 | TACR1 (0.50) | TACR1NOS1NOS2NOS3CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289427-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. | Anagenesis Biotechnologies (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | TACR1 1434/4885NOS1 676/4885NOS2 1534/4885 |
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | TACR1 4251/4885NOS1 1852/4885NOS2 2443/4885 |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | CCNT1, CCNA1, CCND1 | TACR1 2289/4885NOS1 2364/4885NOS2 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.